Related Experiment Video
Updated: Jun 16, 2026
08:03
Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
Novel glitazones: design, synthesis, glucose uptake and structure-activity relationships
B R Prashantha Kumar1, M J Nanjan
1Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Tamilnadu, India.
Bioorganic & Medicinal Chemistry Letters
|February 20, 2010
Summary
Novel glitazone compounds were synthesized and tested for their ability to improve glucose uptake, showing promising antihyperglycemic effects, particularly in the presence of insulin.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Endocrinology
Background:
- Glitazones are recognized for their antihyperglycemic properties, primarily through the reduction of peripheral insulin resistance.
- Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists are a key target for managing hyperglycemia.
Purpose of the Study:
- To design and synthesize novel glitazone derivatives.
- To evaluate the in vitro antihyperglycemic activity of these novel compounds.
- To explore the structure-activity relationships (SAR) of the synthesized glitazones as potential PPAR-gamma agonists.
Main Methods:
- Manual design of glitazone structures based on established SAR.
- Chemical synthesis of the designed glitazone compounds using appropriate synthetic pathways.
- In vitro screening of antihyperglycemic activity by measuring glucose uptake in rat hemi-diaphragm preparations, with and without external insulin.
Main Results:
- Several synthesized glitazone derivatives demonstrated significant antihyperglycemic activity.
- The observed activity was particularly notable in the presence of external insulin.
- Structure-activity relationship analysis provided insights into the design of effective glitazone analogs.
Conclusions:
- The study successfully designed and synthesized novel glitazone compounds with potential antihyperglycemic activity.
- These findings support the development of glitazones as therapeutic agents for managing insulin resistance and hyperglycemia.
- Further investigation into the SAR of these compounds could lead to optimized PPAR-gamma agonists.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...